Recursion Pharmaceuticals, Inc. RXRX Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s total liabilities & equity?
- Recursion Pharmaceuticals, Inc. (RXRX) reported total liabilities & equity of $1.34B in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s total liabilities & equity changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s total liabilities & equity increased by 2.6% year-over-year, from $1.31B to $1.34B.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s total liabilities & equity?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s total liabilities & equity has grown at a 37.6% compound annual growth rate (CAGR), from $298.59M to $1.47B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.